Our novel small-molecule drugs combine targeted and immunotherapeutic mechanisms of action for the treatment of cancer patients with clear unmet medical need and limited treatment options.

HDAC6-selective inhibitors

KA2507, our highly selective HDAC6 inhibitor, continues to be under clinical investigation at The University of Texas MD Anderson Cancer Center. Additionally, it is progressing into Phase II studies at the CRUK-UCL Cancer Trials Centre, London.

Our R&D program is focused on a new generation of brain-penetrant, small molecules targeting glioblastoma and other indications.

Read more

PI3K-selective inhibitors

KA2237, our dual-selective PI3K-p110β/δ inhibitor, has been under investigation in a Phase I clinical trial in patients with relapsed/refractory B-cell lymphoma at The University of Texas MD Anderson Cancer Center, as part of our strategic collaboration. This study has now been completed.

Data from the study, presented at the 2019 American Society of Hematology Annual Meeting, showed an overall response rate of 37 % in 19 evaluable patients with this disease.

Learn more

Lead
Design
Lead
Optimization
Pre-clinical
Development

Phase I

Phase II

KA2507 – Oral, HDAC6-selective inhibitor

Phase I Monotherapy

Dose escalation, solid tumors
ClinicalTrials.gov Identifier – NCT03008018

KA2237 – Oral, PI3K-p110β/δ-selective inhibitor

Phase I Monotherapy

Dose escalation, B-cell lymphomas
ClinicalTrials.gov Identifier – NCT02679196

Non-hydroxamate, HDAC6-targeted inhibitors
including brain-penetrant agents

Development candidates in progress

Potential being explored in cancer and other indications